CardioAbstracts: Congestion

HFSA’s CardioAbstracts program delivers expert-led discussions on recently presented clinical trial data in a convenient, interactive format.

CardioAbstracts Congestion Logo

About CardioAbstracts

HFSA’s CardioAbstracts program delivers expert-led discussions on recently presented clinical trial data in a convenient, interactive format. This 45-minute live seminar features Q&A with leading clinicians, recordings, and downloadable resources available for on-demand learning. This program is designed to support diverse learning styles and provide practical insights for clinicians specializing in heart failure care.

August 5, 2026 | 5:00 PM - 5:45 PM ET | Virtual Livestream; OnDemand to follow

Congestion in chronic heart failure is commonly treated with loop diuretics such as furosemide. Although intravenous administration is effective, it often requires clinic visits or hospitalization. Join HFSA's Cardio Abstract event to review new data on a novel 80 mg/mL subcutaneous furosemide formulation delivered in a single 1.0-mL injection, offering a potentially more convenient treatment option for patients.

Registration is complimentary for all heart failure professionals.

Faculty

Speaker: Tamas Alexy, MD, PhD, FHFSA
The University of Minnesota Medical School (Cardiovascular Division) 

Speaker: John Mohr, PharmD
VaultBio

Speaker: James Udelson, MD
Tufts Medical Center Cardiovascular Center

This program is supported by an independent grant from MannKind Corporation.

Target Audience

Cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.

Educational Statement

CardioAbstracts is a non-accredited educational program that utilizes an online format to provide timely information and the opportunity to interact with faculty and ask questions to find more information about  new data on a novel 80 mg/mL subcutaneous furosemide formulation delivered in a single 1.0-mL injection, offering a potentially more convenient treatment option for patients.